BUZZ-Aeterna Zentaris Inc: To begin late-stage study on hormone drug
** Canadian drug developer's U.S.-listed shares up 6 pct at $0.54; Toronto-listed shares up 6.15 pct at C$0.69
** Says plans to conduct confirmatory study on hormone deficiency drug-test after meeting with U.S. Food and Drug Administration
** FDA rejected the test on Nov. 6 last year
** Up to Friday's close, U.S. shares had fallen 60 pct since test was rejected
© Thomson Reuters 2017 All rights reserved.